Cantor Fitzgerald Weighs in on MDGL FY2026 Earnings

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) – Investment analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for shares of Madrigal Pharmaceuticals in a report released on Monday, June 9th. Cantor Fitzgerald analyst P. Agrawal forecasts that the biopharmaceutical company will post earnings of ($2.78) per share for the year. The consensus estimate for Madrigal Pharmaceuticals’ current full-year earnings is ($23.47) per share.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last announced its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($3.32) EPS for the quarter, beating the consensus estimate of ($3.62) by $0.30. The firm had revenue of $137.25 million for the quarter, compared to analysts’ expectations of $112.79 million. During the same quarter in the prior year, the business posted ($7.38) EPS.

Several other equities research analysts have also recently weighed in on the stock. HC Wainwright upped their price target on shares of Madrigal Pharmaceuticals from $400.00 to $405.00 and gave the stock a “buy” rating in a research report on Thursday, February 27th. Canaccord Genuity Group boosted their price objective on shares of Madrigal Pharmaceuticals from $394.00 to $420.00 and gave the stock a “buy” rating in a research note on Friday, May 2nd. UBS Group upped their target price on Madrigal Pharmaceuticals from $441.00 to $458.00 and gave the stock a “buy” rating in a report on Friday, May 2nd. Citigroup lifted their price target on Madrigal Pharmaceuticals from $378.00 to $469.00 and gave the company a “buy” rating in a report on Thursday, February 27th. Finally, Wall Street Zen raised Madrigal Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, May 5th. Two investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $416.33.

Madrigal Pharmaceuticals Stock Up 0.7%

Shares of Madrigal Pharmaceuticals stock opened at $280.24 on Tuesday. The company has a debt-to-equity ratio of 0.15, a current ratio of 5.98 and a quick ratio of 5.93. The stock has a market cap of $6.22 billion, a price-to-earnings ratio of -11.17 and a beta of -1.08. The firm’s 50-day moving average is $299.01 and its two-hundred day moving average is $315.39. Madrigal Pharmaceuticals has a 1 year low of $200.63 and a 1 year high of $377.46.

Hedge Funds Weigh In On Madrigal Pharmaceuticals

Large investors have recently made changes to their positions in the business. William Blair Investment Management LLC acquired a new stake in shares of Madrigal Pharmaceuticals in the 4th quarter worth $114,717,000. Adage Capital Partners GP L.L.C. raised its stake in Madrigal Pharmaceuticals by 860.0% in the first quarter. Adage Capital Partners GP L.L.C. now owns 191,609 shares of the biopharmaceutical company’s stock valued at $63,467,000 after buying an additional 171,649 shares during the last quarter. Woodline Partners LP boosted its holdings in Madrigal Pharmaceuticals by 110.2% in the fourth quarter. Woodline Partners LP now owns 309,117 shares of the biopharmaceutical company’s stock worth $95,384,000 after acquiring an additional 162,027 shares in the last quarter. Hood River Capital Management LLC acquired a new stake in Madrigal Pharmaceuticals in the fourth quarter worth about $39,447,000. Finally, Renaissance Technologies LLC grew its stake in shares of Madrigal Pharmaceuticals by 261.3% during the fourth quarter. Renaissance Technologies LLC now owns 160,782 shares of the biopharmaceutical company’s stock worth $49,613,000 after acquiring an additional 116,285 shares during the last quarter. 98.50% of the stock is owned by institutional investors and hedge funds.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.